Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
OTC Markets OTCPK - Delayed Quote USD

Inventiva S.A. (IVEVF)

Compare
3.6400
0.0000
(0.00%)
At close: November 18 at 3:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVEVF

Recent News: IVEVF

View More
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
GlobeNewswire 4 days ago
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
GlobeNewswire 14 days ago
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
GlobeNewswire 26 days ago
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
GlobeNewswire last month
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
GlobeNewswire last month
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2 months ago
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
GlobeNewswire 2 months ago
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
GlobeNewswire 2 months ago
Inventiva reports 2024 Third Quarter Financial Information¹

Inventiva reports 2024 Third Quarter Financial Information¹
GlobeNewswire 3 months ago
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
GlobeNewswire 3 months ago
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
GlobeNewswire 3 months ago
View More

Related Tickers

0M4.DU Mersana Therapeutics Inc
0.5254
+7.86%
 
0M4.MU Mersana Therapeutics Inc
0.5166
+1.18%
 
ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.
55.15
+0.64%
 
CARM Carisma Therapeutics, Inc.
0.4420
-1.82%
 
AEON AEON Biopharma, Inc.
0.0675
-43.89%
 
MRSN Mersana Therapeutics, Inc.
0.5566
+4.39%